REBLOZYL J Code: J0896

Drug & Product Overview

HCPCS Descriptor Injection, luspatercept-aamt, 0.25 mg

HCPCS Added Date July 1, 2020

Manufacturer Celgene

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution

About REBLOZYL

Reblozyl is a medication aligned to the HCPCS J Code: J0896 for billing, pricing, and reimbursement purposes in the United States. Classified under Anti-Anemia, it is administered via the subcutaneous route and manufactured by Celgene.

According to CMS Drug Use Information: This medication is used to treat anemia caused by certain blood and bone marrow disorders (such as beta thalassemia, myelodysplastic syndromes). In these conditions, your body does not make enough healthy red blood cells. This medication is thought to work by increasing your body's production of healthy red blood cells and hemoglobin. This effect may lessen your symptoms caused by anemia and decrease your need for regular blood transfusions.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
59572-0711-01	Reblozyl	Celgene Corporation	100	25 MG
59572-0775-01	Reblozyl	Celgene Corporation	300	75 MG

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

REBLOZYL Pricing & Reimbursement

J0896 Private Payer Reimbursement

$42.58 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

REBLOZYL Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 9.64%

Avg. Days to File 6.9days

Avg. Days to Pay 24.4days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J0896 claims analytics on FocalPoint →

REBLOZYL CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

JW / JZ modifiers apply

CMS has identified Reblozyl (J0896) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

REBLOZYL Medically Unlikely Edits (MUE)

The most billing units of J0896 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.25 mg.

Practitioner Office & Hospital Outpatient

1,100 units / day

= 275 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

REBLOZYL Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Anemia associated with MDS-RS or MDS/MPN-RS-T (ESA-refractory) Anemia associated with myelodysplastic syndromes (ESA-naïve) Anemia in beta thalassemia

Drug Class

Erythroid Maturation Agent [EPC]Increased Erythroid Cell Production [PE]

Frequently Asked Questions

Is there an available Reblozyl billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for REBLOZYL.

Are there any available Reblozyl patient assistance programs?

REBLOZYL patient assistance information can be found through Celgene. Visit Here →

Where can I find Reblozyl prescribing information?

REBLOZYL prescribing information can be found at the link below: Visit Here →

Where can I find Reblozyl side effect information?

Information regarding REBLOZYL's side effects can be found at MedlinePlus Visit Here →

Does billing REBLOZYL require JZ/JW wastage modifiers?

CMS has identified REBLOZYL(J0896) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.